pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,833 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1853Endpoints1439Fierce Biotech757BioSpace744BioPharma Dive544raps249onclive165fda recalls118
therapy area
allOncology12823Rare Disease3324Immunology2980Cardiology2845Hematology2283Pulmonology2229Vaccines
  • Minghui licenses sub-q TED drug to Japan's ASKA in up to $440 million deal
    Minghui Pharmaceutical of China has signed a licensing agreement with Japan's ASKA Pharmaceutical, granting exclusive rights to develop and sell its late‑stage thyroid eye disease (TED) candidate i…
    Fierce Biotech · 14d agoDealPositive↗ source
  • Blackstone Life Sciences and Boston Scientific launch $455 million partnership to develop next-generation heart pump
    Blackstone Life Sciences has entered a collaboration with Boston Scientific, committing $455 million to co‑fund development of a next‑generation miniature heart pump system. The device, called the…
    Fierce Biotech · 14d agoDealPositive↗ source
← prev
page 8 of 74
next →
fda medwatch114
globenewswire health73
fda press61
1844
Psychiatry & CNS1229
Ophthalmology1128
Endocrinology & Metabolism805
Pain789
Nephrology782
  • AbbVie pays $100M upfront in $1.4B deal for Nxera's phase-1 IBD candidate
    AbbVie has agreed to pay $100 million upfront for the worldwide rights to Nxera's oral EP4 receptor agonist, designated NXE0033744, with the total deal value potentially reaching $1.4 billion throu…
    Fierce Biotech · 14d agoDealPositive↗ source
  • Ultragenyx to cut 20% of staff and halve R&D budget as it pivots to commercial sales
    Ultragenyx announced it will reduce its workforce by about 20%, bringing headcount down to roughly 1,000 employees. The cuts follow an earlier 10% reduction announced in February and are part of a…
    Fierce Biotech · 14d agoLayoffsNegative↗ source
  • Sanofi halts development of Nurix-partnered STAT6 degrader, triggering sharp drop in Nurix stock
    Sanofi announced it is ending work on SAR448272, an experimental oral drug that was intended to degrade the STAT6 protein, which is linked to inflammatory diseases. The biotech firm Nurix, which l…
    BioPharma Dive · 13d agoNegative↗ source
  • Analysts predict biopharma gains as Democrats take Congress control
    Analysts say the biopharma sector is set to benefit from the recent shift in U.S. Congress, with Democrats now holding majorities in both the House and Senate. They note that drug‑pricing debates…
    BioPharma Dive · 13d agoPositive↗ source
  • Charles River partners with Ipsen to employ virtual control groups in toxicology studies
    Charles River Laboratories and French biopharma Ipsen announced a collaboration to use Charles River’s virtual control group (VCG) database in an upcoming toxicology study. The VCG approach aims t…
    Fierce Biotech · 13d agoDealPositive↗ source
  • FDA urges biosimilar sponsors to use alternative efficacy studies while AI reshapes regulatory work
    AI is becoming common in regulatory work. Experts say it will not replace regulatory professionals but will help them work more efficiently and free up time for human interaction. They stress that…
    raps · 14d agoRegulatoryNeutral↗ source
  • nPhase secures $30M Series D to grow AI-driven clinical data platform
    CRO nPhase announced it has closed a $30 million Series D financing round. The capital will be directed toward expanding its AI-native clinical data platform that debuted in September, which aims t…
    Fierce Biotech · 14d agoDealPositive↗ source
  • Smith+Nephew ends talks with J&J on orthopedics merger as growth stalls
    Smith+Nephew announced that discussions with Johnson & Johnson’s DePuy Synthes about a possible orthopedics combination have ended. The talks were disclosed in the company’s third‑quarter release;…
    Fierce Biotech · 14d agoDealNegative↗ source
  • FDA urges biosimilar makers to adopt alternatives to clinical efficacy trials
    FDA's Office of Therapeutic Biologics and Biosimilars, led by director Sarah Yim, announced that the agency is working to help sponsors rely less on clinical efficacy studies when developing biosim…
    raps · 14d agoRegulatoryPositive↗ source
  • Sanofi halts Nurix STAT6 degrader program two months after phase-1 start
    Sanofi announced it is ending its collaboration with Nurix on a STAT6 degrader, just two months after the drug entered a phase-1 study. The two companies have worked together since 2019, with Sano…
    Fierce Biotech · 14d agoDealNegative↗ source
  • MiniMed appoints diabetes and digital health veteran David Segal as chief medical officer
    MiniMed, the insulin pump maker that spun off from Medtronic, announced the appointment of Dr. David Segal as its new chief medical officer. Segal replaces Dr. Robert Vigersky, who has served as C…
    Fierce Biotech · 14d agoPositive↗ source
  • T-Therapeutics secures $133M Series B to advance TCR-CD3 bispecifics with major pharma investors
    T-Therapeutics announced a $133 million Series B financing round backed by several of the world’s largest drug developers, including Eli Lilly, Johnson & Johnson, Merck KGaA and Sanofi, along with…
    Fierce Biotech · 14d agoDealPositive↗ source
  • Medicare Part D premiums expected to rise 50% on average in 2027, KFF warns seniors to compare plans
    KFF analysis shows average monthly premiums for Medicare Part D standalone plans will jump from $34 to $51 in 2027, a 50% increase if seniors stay in their current plans. Premiums vary widely acro…
    BioPharma Dive · 14d agoRegulatoryNegative↗ source
  • Rhythm Pharmaceuticals expands LG Chem obesity drug license, total payout up to $855 million
    Rhythm Pharmaceuticals and LG Chem have revised their licensing agreement for the oral obesity and hyperphagia drug bivamelagon, increasing the total scheduled payments. The new terms raise the po…
    Fierce Biotech · 15d agoDealPositive↗ source
  • Philips earmarks $322 million for pending DOJ settlement on sleep-apnea device recall
    Philips' Respironics division announced it has reached an agreement in principle with the U.S. Department of Justice to settle the investigation into its sleep‑apnea device recall. The recall, ini…
    Fierce Biotech · 15d agoRegulatoryNegative↗ source
  • UniQure slated for FDA decision by May 1 as analysts see potential for first Huntington’s disease therapy
    UniQure said the Food and Drug Administration has set a decision date for its Huntington's disease gene therapy and is likely to hold an advisory committee meeting. The agency indicated a faster‑th…
    BioPharma Dive · 14d agoRegulatoryNeutral↗ source
  • Pfizer drops phase 2 pulmonary arterial hypertension candidate amid pipeline cut
    Pfizer has discontinued its phase 2 pulmonary arterial hypertension (PAH) program, PF-07868489, citing business reasons rather than safety or efficacy concerns. The drug, which targets BMP9 inhibi…
    Fierce Biotech · 15d agoNegative↗ source
  • AbbVie commits £120 million to new Oxford R&D hub, boosting UK life‑science footprint
    AbbVie announced a £120 million ($160 million) investment to expand its research footprint in the United Kingdom. The company will open a new 12,000‑square‑foot R&D facility in Oxford, joining its…
    Fierce Biotech · 15d agoDealPositive↗ source
  • Novartis ends $800M neuroscience partnership with BioArctic after 14 months
    Novartis signed an $800 million neuroscience partnership with BioArctic in August 2025, providing $30 million upfront to merge BioArctic’s BrainTransporter technology with a Novartis antibody targe…
    Fierce Biotech · 15d agoDealNegative↗ source
  • Abbott reports 30‑day success in Tectonic trial of SonicForce coronary IVL system
    Abbott announced that its investigational SonicForce Coronary IVL system achieved positive 30‑day outcomes in the Tectonic trial involving patients with severely calcified coronary artery disease.…
    Fierce Biotech · 15d agoPositive readoutPositive↗ source
  • Legal experts advise European healthcare manufacturers on navigating complex environmental regulations
    At the RAPS Regulatory Intelligence Conference Europe in Barcelona, two legal specialists highlighted the difficulty of Europe’s environmental and sustainability rules for companies that make healt…
    raps · 15d agoRegulatoryNeutral↗ source
  • FDA reports rise in unannounced drug inspections in China and India for FY 2026
    A senior FDA enforcement official said the agency carried out more surprise drug facility inspections in India and China during fiscal year 2026 than it did in the prior year. The unannounced visi…
    raps · 15d agoRegulatoryNeutral↗ source
  • Advanced analytics enable up to 12% cut in control animal use while keeping study rigor
    The control group is a cornerstone of nonclinical safety studies, providing the baseline needed to separate a drug’s effects from normal biological variation. Researchers are now applying virtual…
    Fierce Biotech · 14d agoPositive↗ source